Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248936 · ClinicalTrials.gov registry record · Phase 2
A Study of RO5185426 in Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 374
- Enrollment target
NCT01248936: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT01248936 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 374 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (181% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01248936, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 374 participants
- Enrollment target
Study Summary
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
Primary Outcome
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs will be graded according to the 'National Cancer Institute Common Terminology Criteria for Adverse Events' (NCI CTCAE, v4.0). However Laboratory data will be summarized by grade using the NCI CTCAE, v4.0 toxicity grade.
Interventions
- DRUG RO5185426
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT01248936 record still lists
NCT01248936 is an interventional study that assigns participants to a tested intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (181% higher).
The record links to 0 conditions, and to 1 intervention - of which RO5185426 is the first listed.
NCT01248936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01248936 about?
NCT01248936 is a clinical study titled "A Study of RO5185426 in Patients With Metastatic Melanoma". This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
What is the current status of trial NCT01248936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 374 participants. The study started on 2010-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01248936?
The interventions under investigation include: RO5185426 (DRUG).
Who is sponsoring clinical trial NCT01248936?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01248936's enrollment target sits among peer trials
374 118th of 2000 higher than 1,883 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia